A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-19

Study Completion Date

2024-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the safety and efficacy of JZP341 in participants with advanced or metastatic solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

NCT00121290

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

NCT05653661

Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Melanoma

WITHDRAWN PHASE1

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819

Solid Tumor

RECRUITING PHASE1/PHASE2

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094

Advanced Solid Tumors HER2-positive Breast Cancer

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

NCT03926013

Neoplasms

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a first-in-human, open-label, multiple-dose, phase 1, multicenter, dose-finding study of single-agent JZP341 followed by a targeted expansion phase.

This study will have 2 phases: Dose Finding Phase and Dose Expansion Phase.

The Dose-Finding Phase will determine the recommended phase 2 dose (RP2D), assess safety and pharmacokinetics/pharmacodynamics, and explore preliminary antitumor activity of JZP341 in participants with relapsed or refractory advanced solid tumors.

The Dose-Expansion Phase will evaluate clinical activity and further evaluate the safety of multiple doses of single-agent JZP341 at the RP2D in participants with relapsed or refractory colorectal adenocarcinoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumor Metastatic Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Finding Phase: JZP341

Participants who will receive JZP341 on Day 1 and Day 15 of each 28-day cycle.

Group Type EXPERIMENTAL

JZP341

Intervention Type DRUG

JZP341 will be administered as a single, intravenous infusion over 2 hours.

Dose Expansion Phase: JZP341

Participants who will receive JZP341 at the RP2D established in the Dose Finding Phase on Day 1 and Day 15 of each 28-day cycle.

Group Type EXPERIMENTAL

JZP341

Intervention Type DRUG

JZP341 will be administered as a single, intravenous infusion over 2 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JZP341

JZP341 will be administered as a single, intravenous infusion over 2 hours.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent form (ICF)
* ≥ 18 years of age at the time of signing the ICF
* Eastern Cooperative Oncology Group performance status of 0 to 2
* Adequate bone marrow reserve
* Adequate coagulation function, liver/pancreas function, and renal function
* No clinically significant abnormalities in the levels of serum electrolytes
* Life expectancy \>12 weeks
* Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 3 months after the last dose of study intervention:

* Refrain from donating sperm, AND either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR
* Must agree to use an approved contraception method
* A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

* Woman of non-childbearing potential (WONCBP)
* Woman of childbearing potential (WOCBP) and using an effective contraceptive method
* A WOCBP must have a negative highly sensitive pregnancy test within 72 hours of the first dose of study intervention

* Have a histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumor that has progressed after prior standard therapy, been intolerant to or is ineligible for standard therapy, or has a malignancy for which there is no approved therapy considered standard of care

* Histologically or cytologically confirmed colorectal adenocarcinoma that has progressed on or is intolerant to treatment from fluoropyrimidine, oxaliplatin, and irinotecan. Participants may have received bevacizumab, anti-epidermal growth factor receptor monoclonal antibody, or checkpoint inhibitor as appropriate.
* Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 criteria

Exclusion Criteria

* Primary central nervous system (CNS) tumor or symptomatic CNS metastases that are neurologically unstable or have required increasing doses of steroids within the 4 weeks prior to study entry to manage CNS symptoms (symptomatic brain metastases that have been adequately treated are not excluded)
* Any clinically significant cardiac disease defined as New York Heart Association class III or IV within the 6 months before Screening
* History of ≥ Grade 3 pancreatitis
* History of intracranial thrombosis or history of recurrent thrombosis (except for catheter-related thrombosis)
* Active (significant or uncontrolled) gastrointestinal bleeding
* Active uncontrolled infection (≥ Grade 2) at the time of enrollment
* HIV-positive, unless:

* CD4+ count ≥ 300/μL;
* Undetectable viral load; AND
* Receiving highly active antiretroviral therapy
* Uncontrolled infection of hepatitis B or hepatitis C or diagnosis of immunodeficiency

* Participants with Hepatitis B who have controlled infection are permitted. Participants with controlled infections must undergo periodic monitoring of Hepatitis B virus DNA. Participants must remain on antiviral therapy for ≥ 6 months beyond the last dose of study intervention.
* Pregnant (or plan to be pregnant) or lactating woman
* History of any severe or uncontrolled medical condition
* Unresolved toxicity, based on the investigator's assessment of the participant, from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment, except for stable conditions ≤Grade 2 (ie, neuropathy, myalgia, fatigue, alopecia, therapy-related endocrinopathies)
* Prior treatment with JZP341 or any other asparaginase

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No